LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Search

Ligand Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

194.64 -3.63

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

193.84

Max

199.02

Belangrijke statistieken

By Trading Economics

Inkomsten

-72M

45M

Verkoop

-56M

60M

K/W

Sectorgemiddelde

32.685

57.05

Winstmarge

75.058

Werknemers

47

EBITDA

-83M

66M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+22.81% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

381M

4B

Vorige openingsprijs

198.27

Vorige sluitingsprijs

194.64

Nieuwssentiment

By Acuity

50%

50%

158 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mrt 2026, 17:33 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mrt 2026, 17:00 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mrt 2026, 16:03 UTC

Belangrijke Nieuwsgebeurtenissen

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 mrt 2026, 14:50 UTC

Belangrijke Marktbewegers

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 mrt 2026, 14:37 UTC

Acquisities, Fusies, Overnames

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 mrt 2026, 14:29 UTC

Belangrijke Nieuwsgebeurtenissen

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27 mrt 2026, 14:16 UTC

Belangrijke Nieuwsgebeurtenissen

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 19:16 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mrt 2026, 19:07 UTC

Marktinformatie

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mrt 2026, 19:04 UTC

Marktinformatie

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mrt 2026, 19:03 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 19:02 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mrt 2026, 18:12 UTC

Marktinformatie

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mrt 2026, 17:36 UTC

Belangrijke Nieuwsgebeurtenissen

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mrt 2026, 17:34 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mrt 2026, 17:29 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mrt 2026, 16:38 UTC

Marktinformatie

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mrt 2026, 16:32 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mrt 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 15:43 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 mrt 2026, 14:36 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 mrt 2026, 14:26 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27 mrt 2026, 14:14 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 14:14 UTC

Marktinformatie

Global Energy Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ligand Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

22.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 250.17 USD  22.81%

Hoogste 277 USD

Laagste 230 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ligand Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

102.5 / 109.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

158 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat